medigraphic.com
ISSN 0028-3851 (Print)

2018, Number 2

<< Back

Rev Neurol Neurocir Psiquiat 2018; 46 (2)

Metabolic consequences of sleep apnea

Uribe WAC

Language: Spanish
References: 16
Page: 65-71
PDF size: 262.87 Kb.


ABSTRACT

Obstructive sleep (OSA) is a highly prevalent condition with relevant cardiovascular and metabolic complications. It is associated with hypertension, obesity, insulin resistance, diabetes, dyslipidemia and metabolic syndrome, and its severity correlates with degree of complications. It generates oxidative stress with the activation of the inflammatory cascade and the release of chemical mediators which impair metabolic regulation. The inflammatory response generated by OSA will be described in this article, along with its relationship with hypertension, obesity, insulin resistance and metabolic syndrome.


REFERENCES

  1. Bonsignore MR, Borel AL, Machan E, Grunstein R. Sleep apnea and metabolic dysfunction. Eur Respir Rev. 2013; 22: 353-364.

  2. Alva y Pérez JL. Consecuencias metabólicas y cardiovasculares del síndrome de apnea obstructiva del sueño. Med Int Mex. 2009; 25 (2): 116-128.

  3. Attal P, Chanson P. Endocrine aspects of obstructive sleep apnea. J Clin Endocrinol Metab. 2010; 95 (5): 483-495.

  4. Mesarwi OA, Sharma EV, Jun JC, Polotsky VY. Metabolic dysfunction in obstructive sleep apnea: A critical examination of underlying mechanisms. Sleep Biol Rhythms. 2015; 13 (1): 2-17.

  5. Chopra S, Rathore A, Younas H, Pham LV, Gu C, Beselman A et al. Obstructive sleep apnea dynamically increases nocturnal plasma free fatty acids, glucose, and cortisol during sleep. J Clin Endocrinol Metab. 2017; 102 (9): 3172-3181.

  6. Codoceo R. Síndrome de apnea obstructiva del sueño y alteración en la tolerancia a la glucosa. Rev Med Clin Condes. 2013; 24 (3): 422-431.

  7. Bonsignore MR, McNicholas WT, Montserrat JM, Eckel J. Adipose tissue in obesity and obstructive sleep apnoea. Eur Respir J. 2012; 39: 746-767.

  8. Stansbury RC, Strollo PJ. Clinical manifestations of sleep apnea. J Thorac Dis. 2015; 7 (9): E298-E310.

  9. Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE et al. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol. 2004; 160 (6): 521-530.

  10. Ruchała M, Bromińska B, Cyrańska-Chyrek E, Kuźnar-Kamińska B, Kostrzewska M, Batura-Gabryel H. Obstructive sleep apnea and hormones-a novel insight. Arch Med Sci. 2017; 13 (4): 875-884.

  11. Jun JC, Chopra S, Schwartz AR. Sleep apnoea. Eur Respir Rev. 2016; 25: 12-18.

  12. Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers VK. Interactions between obesity and obstructive sleep apnea. Implications for treatment. Chest. 2010; 137 (3): 711-719.

  13. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab. 2000; 85 (3): 1151-1158.

  14. Doumit J, Prasad B. Sleep apnea in type 2 diabetes. Diabetes Spectrum. 2016; 29 (1): 14-19.

  15. Sharma SK, Agrawal S, Damodaran D, Sreenivas V, Kadhiravan T, Lakshmy R et al. CPAP for the metabolic syndrome in patients with obstructive sleep apnea. N Engl J Med. 2011; 364 (24): 2277-2286.

  16. Depner CM, Stothard E, Wright KP. Metabolic consequences of sleep and circadian disorders. Curr Diab Rep. 2014; 14 (7): 1-15.




2020     |     www.medigraphic.com